T cell apoptosis and induction of foxp3 + regulatory T cells underlie the therapeutic efficacy of CD4 blockade in experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 189, Issue 4, 2012, Pages 1680-1688

  Duarte, Joana ^a,b   Carrié, Nadège ^c,d   Oliveira, Vanessa G ^a,b   Almeida, Catarina ^a,b   Agua Doce, Ana ^a,b   Rodrigues, Lénia ^a,b   Simas, J Pedro ^a,b   Mars, Lennart T ^c,d   Graca, Luis ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^c CNRS   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; MONOCLONAL ANTIBODY; NEUROANTIGEN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; YTS 177;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL DIVISION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GROWTH INHIBITION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD4; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FLOW CYTOMETRY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84864827341     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201269     Document Type: Article

References (68)

1. Compston, A., and A. Coles. 2008. Multiple sclerosis. Lancet 372: 1502-1517.
2. Sospedra, M., and R. Martin. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23: 683-747. (Pubitemid 40563183)
3. Gregory, S. G., S. Schmidt, P. Seth, J. R. Oksenberg, J. Hart, A. Prokop, S. J. Caillier, M. Ban, A. Goris, L. F. Barcellos, et al Multiple Sclerosis Genetics Group. 2007. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 39: 1083-1091. (Pubitemid 47340652)
4. Hafler, D. A., A. Compston, S. Sawcer, E. S. Lander, M. J. Daly, P. L. De Jager, P. I. de Bakker, S. B. Gabriel, D. B. Mirel, A. J. Ivinson, et al International Multiple Sclerosis Genetics Consortium. 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357: 851-862. (Pubitemid 47347319)
5. Jagodic, M., C. Colacios, R. Nohra, A. S. Dejean, A. D. Beyeen, M. Khademi, A. Casemayou, L. Lamouroux, C. Duthoit, O. Papapietro, et al. 2009. A role for VAV1 in experimental autoimmune encephalomyelitis and multiple sclerosis. Sci. Transl. Med. 1: 10ra21.
6. Lundmark, F., K. Duvefelt, E. Iacobaeus, I. Kockum, E.Wallström, M. Khademi, A. Oturai, L. P. Ryder, J. Saarela, H. F. Harbo, et al. 2007. Variation in interleukin 7 receptor a chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 39: 1108-1113. (Pubitemid 47340654)
7. Sawcer, S., G. Hellenthal, M. Pirinen, C. C. Spencer, N. A. Patsopoulos, L. Moutsianas, A. Dilthey, Z. Su, C. Freeman, S. E. Hunt, et al International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
8. Jersild, C., A. Svejgaard, and T. Fog. 1972. HL-A antigens and multiple sclerosis. Lancet 1: 1240-1241.
9. Hauser, S. L., A. K. Bhan, F. Gilles, M. Kemp, C. Kerr, and H. L. Weiner. 1986. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann. Neurol. 19: 578-587. (Pubitemid 16085192)
10. Goverman, J. 2009. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9: 393-407.
11. Gold, R., C. Linington, and H. Lassmann. 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129: 1953-1971. (Pubitemid 44289062)
12. Codarri, L., G. Gyülvészi, V. Tosevski, L. Hesske, A. Fontana, L. Magnenat, T. Suter, and B. Becher. 2011. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12: 560-567.
13. H17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 12: 568-575.
14. Ponomarev, E. D., L. P. Shriver, K. Maresz, J. Pedras-Vasconcelos, D. Verthelyi, and B. N. Dittel. 2007. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J. Immunol. 178: 39-48. (Pubitemid 46039660)
15. Awasthi, A., G. Murugaiyan, and V. K. Kuchroo. 2008. Interplay between effector Th17 and regulatory T cells. J. Clin. Immunol. 28: 660-670.
16. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169: 4712-4716.
17. +regulatory cells within the central nervous system. J. Immunol. 175: 3025-3032.
18. Coles, A. J., D. A. Compston, K.W. Selmaj, S. L. Lake, S. Moran, D. H. Margolin, K. Norris, and P. K. Tandon; CAMMS223 Trial Investigators. 2008. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med. 359: 1786-1801.
19. Miller, D. H., O. A. Khan, W. A. Sheremata, L. D. Blumhardt, G. P. Rice, M. A. Libonati, A. J. Willmer-Hulme, C. M. Dalton, K. A. Miszkiel, and P. W. O'Connor; International Natalizumab Multiple Sclerosis Trial Group. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348: 15-23. (Pubitemid 36026342)
20. Polman, C. H., P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, J. T. Phillips, F. D. Lublin, G. Giovannoni, A. Wajgt, et al AFFIRM Investigators. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354: 899-910.
21. Yednock, T. A., C. Cannon, L. C. Fritz, F. Sanchez-Madrid, L. Steinman, and N. Karin. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 356: 63-66.
22. Hohlfeld, R., and H. Wekerle. 2005. Drug insight: using monoclonal antibodies to treat multiple sclerosis. Nat. Clin. Pract. Neurol. 1: 34-44.
23. Cohen, J. A., F. Barkhof, G. Comi, H. P. Hartung, B. O. Khatri, X. Montalban, J. Pelletier, R. Capra, P. Gallo, G. Izquierdo, et al TRANSFORMS Study Group. 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362: 402-415.
24. Fujino, M., N. Funeshima, Y. Kitazawa, H. Kimura, H. Amemiya, S. Suzuki, and X. K. Li. 2003. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 305: 70-77. (Pubitemid 36378136)
25. Howard, L. M., A. J. Miga, C. L. Vanderlugt, M. C. Dal Canto, J. D. Laman, R. J. Noelle, and S. D. Miller. 1999. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. 103: 281-290. (Pubitemid 29053146)
26. + T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J. Immunol. 174: 4525-4534.
27. +T cells. Nat. Med. 12: 627-635.
28. Perruche, S., P. Zhang, Y. Liu, P. Saas, J. A. Bluestone, and W. Chen. 2008. CD3-specific antibody-induced immune tolerance involves transforming growth factor-β from phagocytes digesting apoptotic T cells. Nat. Med. 14: 528-535. (Pubitemid 351655213)
29. Herold, K. C., W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin, and J. A. Bluestone. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346: 1692-1698. (Pubitemid 34547482)
30. Keymeulen, B., E. Vandemeulebroucke, A. G. Ziegler, C. Mathieu, L. Kaufman, G. Hale, F. Gorus, M. Goldman, M. Walter, S. Candon, et al. 2005. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352: 2598-2608. (Pubitemid 41007846)
31. Utset, T. O., J. A. Auger, D. Peace, R. A. Zivin, D. Xu, L. Jolliffe, M. L. Alegre, J. A. Bluestone, and M. R. Clark. 2002. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J. Rheumatol. 29: 1907-1913. (Pubitemid 34988699)
32. Brostoff, S. W., and D. W. Mason. 1984. Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells. J. Immunol. 133: 1938-1942. (Pubitemid 14035289)
33. Graca, L., A. Le Moine, S. P. Cobbold, and H. Waldmann. 2003. Antibody-induced transplantation tolerance: the role of dominant regulation. Immunol. Res. 28: 181-191. (Pubitemid 38091058)
34. Hutchings, P., L. O'Reilly, N. M. Parish, H.Waldmann, and A. Cooke. 1992. The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice. Eur. J. Immunol. 22: 1913-1918.
35. Mauri, C., C. Q. Chu, D. Woodrow, L. Mori, and M. Londei. 1997. Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody. J. Immunol. 159: 5032-5041. (Pubitemid 127471042)
36. Rose, J. W., J. Foley, and N. Carlson. 2008. Monoclonal antibody treatments for multiple sclerosis. Curr. Neurol. Neurosci. Rep. 8: 419-426.
37. + cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig. J. Immunol. 156: 1262-1268.
38. Hutchings, P. R., A. Cooke, K. Dawe, H. Waldmann, and I. M. Roitt. 1993. Active suppression induced by anti-CD4. Eur. J. Immunol. 23: 965-968. (Pubitemid 23101087)
39. + T cell-mediated resistance by a nondepleting rat CD4 monoclonal antibody. Cell. Immunol. 138: 185-196.
40. Rose, L. M., E. C. Alvord, Jr., S. Hruby, S. Jackevicius, R. Petersen, N. Warner, and E. A. Clark. 1987. In vivo administration of anti-CD4 monoclonal antibody prolongs survival in longtailed macaques with experimental allergic encephalomyelitis. Clin. Immunol. Immunopathol. 45: 405-423. (Pubitemid 18005918)
41. Sedgwick, J. D., and D. W. Mason. 1986. The mechanism of inhibition of experimental allergic encephalomyelitis in the rat by monoclonal antibody against CD4. J. Neuroimmunol. 13: 217-232. (Pubitemid 17171361)
42. Qin, S., S. P. Cobbold, H. Pope, J. Elliott, D. Kioussis, J. Davies, and H. Waldmann. 1993. "Infectious" transplantation tolerance. Science 259: 974-977.
43. Graca, L., K. Honey, E. Adams, S. P. Cobbold, and H. Waldmann. 2000. Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J. Immunol. 165: 4783-4786.
44. Biasi, G., A. Facchinetti, G. Monastra, S. Mezzalira, S. Sivieri, B. Tavolato, and P. Gallo. 1997. Protection from experimental autoimmune encephalomyelitis (EAE): non-depleting anti-CD4 mAb treatment induces peripheral T-cell tolerance to MBP in PL/J mice. J. Neuroimmunol. 73: 117-123. (Pubitemid 27105277)
45. O'Neill, J. K., D. Baker, A. N. Davison, S. J. Allen, C. Butter, H. Waldmann, and J. L. Turk. 1993. Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies. J. Neuroimmunol. 45: 1-14. (Pubitemid 23224375)
46. Waldor, M. K., D. Mitchell, T. J. Kipps, L. A. Herzenberg, and L. Steinman. 1987. Importance of immunoglobulin isotype in therapy of experimental autoimmune encephalomyelitis with monoclonal anti-CD4 antibody. J. Immunol. 139: 3660-3664. (Pubitemid 18013637)
47. van Oosten, B. W., M. Lai, F. Barkhof, D. H. Miller, I. F. Moseley, A. J. Thompson, S. Hodgkinson, and C. H. Polman. 1996. A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. Mult. Scler. 1: 339-342. (Pubitemid 126701294)
48. van Oosten, B. W., M. Lai, S. Hodgkinson, F. Barkhof, D. H. Miller, I. F. Moseley, A. J. Thompson, P. Rudge, A. McDougall, J. G. McLeod, et al. 1997. Treatment of multiple sclerosis with the monoclonal anti-CD4 anti-body cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 49: 351-357.
49. Lafaille, J. J., K. Nagashima, M. Katsuki, and S. Tonegawa. 1994. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 78: 399-408. (Pubitemid 24250805)
50. Bettelli, E., M. Pagany, H. L. Weiner, C. Linington, R. A. Sobel, and V. K. Kuchroo. 2003. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med. 197: 1073-1081. (Pubitemid 36570063)
51. +T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J. Exp. Med. 188: 1883-1894.
52. + regulatory T cells. Eur. J. Immunol. 41: 1249-1255.
53. + T cells. J. Exp. Med. 184: 863-871.
54. Mars, L. T., L. Araujo, P. Kerschen, S. Diem, E. Bourgeois, L. P. Van, N. Carrié, M. Dy, R. S. Liblau, and A. Herbelin. 2009. Invariant NKT cells inhibit development of the Th17 lineage. Proc. Natl. Acad. Sci. USA 106: 6238-6243.
55. Krishnamoorthy, G., A. Saxena, L. T. Mars, H. S. Domingues, R. Mentele, A. Ben-Nun, H. Lassmann, K. Dornmair, F. C. Kurschus, R. S. Liblau, and H. Wekerle. 2009. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat. Med. 15: 626-632.
56. Mucida, D., N. Kutchukhidze, A. Erazo, M. Russo, J. J. Lafaille, and M. A. Curotto de Lafaille. 2005. Oral tolerance in the absence of naturally occurring Tregs. J. Clin. Invest. 115: 1923-1933. (Pubitemid 40979732)
57. Scheikl, T., B. Pignolet, L. T. Mars, and R. S. Liblau. 2010. Transgenic mouse models of multiple sclerosis. Cell. Mol. Life Sci. 67: 4011-4034.
58. Jones, J. L., and A. J. Coles. 2010. New treatment strategies in multiple sclerosis. Exp. Neurol. 225: 34-39.
59. Tran, G. T., N. Carter, X. Y. He, T. S. Spicer, K. M. Plain, M. Nicolls, B. M. Hall, and S. J. Hodgkinson. 2001. Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on Th1 cells that is augmented by IL-4. Int. Immunol. 13: 1109-1120. (Pubitemid 32899153)
60. Qin, S. X., S. Cobbold, R. Benjamin, and H. Waldmann. 1989. Induction of classical transplantation tolerance in the adult. J. Exp. Med. 169: 779-794. (Pubitemid 19085820)
61. Duarte, J., A. Agua-Doce, V. G. Oliveira, J. E. Fonseca, and L. Graca. 2010. Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice. PLoS ONE 5: e10558.
62. Agua-Doce, A., and L. Graca. 2011. Prevention of house dust mite induced allergic airways disease in mice through immune tolerance. PLoS ONE 6: e22320.
63. Duarte, J., M. Caridade, and L. Graca. 2011. CD4 blockade can induce protection from peanut-induced anaphylaxis. Front. Immunol. 2: 56.
64. Furtado, G. C., M. C. Marcondes, J. A. Latkowski, J. Tsai, A. Wensky, and J. J. Lafaille. 2008. Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis. J. Immunol. 181: 4648-4655.
65. Korn, T., J. Reddy, W. Gao, E. Bettelli, A. Awasthi, T. R. Petersen, B. T. Bäckström, R. A. Sobel, K. W. Wucherpfennig, T. B. Strom, et al. 2007. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13: 423-431. (Pubitemid 46559831)
66. Hori, S., M. Haury, J. J. Lafaille, J. Demengeot, and A. Coutinho. 2002. Peripheral expansion of thymus-derived regulatory cells in anti-myelin basic protein T cell receptor transgenic mice. Eur. J. Immunol. 32: 3729-3735. (Pubitemid 36032656)
67. + T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice. J. Exp. Med. 188: 1875-1882.
68. Graca, L., T. C. Chen, A. Le Moine, S. P. Cobbold, D. Howie, and H. Waldmann. 2005. Dominant tolerance: activation thresholds for peripheral generation of regulatory T cells. Trends Immunol. 26: 130-135. (Pubitemid 40312519)